Year: 2020
Type: article
Abstract: Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.
Source: Cancer Discovery
Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, American Association For Cancer Research, University of Michigan, U-M Rogel Cancer Center, Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, University of Pennsylvania, Institut Gustave Roussy, Fondation Gustave Roussy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: National Cancer Institute
Awards: G183821942, G562087445
OpenAlex ID: W3116049377